[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
For the positron emission tomography (PET) imaging of prostate cancer, radiotracers targeting the prostate-specific membrane antigen (PSMA) are nowadays used in clinical practice. Almost 10 years after its discovery, [<sup>68</sup>Ga]Ga-PSMA-11 has been approved in the United States by t...
Main Authors: | Ute Hennrich, Matthias Eder |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/8/713 |
Similar Items
-
[<sup>68</sup>Ga]Ga-DOTA-TOC: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging
by: Ute Hennrich, et al.
Published: (2020-03-01) -
Diagnostic Performance of [<sup>18</sup>F]Fluorocholine and [<sup>68</sup>Ga]Ga-PSMA PET/CT in Prostate Cancer: A Comparative Study
by: Zeinab Paymani, et al.
Published: (2020-07-01) -
Preclinical Assessment Addressing Intravenous Administration of a [<sup>68</sup>Ga]Ga-PSMA-617 Microemulsion: Acute In Vivo Toxicity, Tolerability, PET Imaging, and Biodistribution
by: Vusani Mandiwana, et al.
Published: (2021-04-01) -
Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [<sup>68</sup>Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
by: Jing Zhao, et al.
Published: (2020-11-01) -
Impact of the Noise Penalty Factor on Quantification in Bayesian Penalized Likelihood (Q.Clear) Reconstructions of <sup>68</sup>Ga-PSMA PET/CT Scans
by: Sjoerd Rijnsdorp, et al.
Published: (2021-05-01)